Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Graph

CLDX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $22.00K; Research and development $67.54M; Income tax (m); Net income -$73.50M.
  • 2026-03-31: Revenue $15.00K; Research and development $73.00M; Income tax (m); Net income -$78.69M.
  • 2025-12-31: Revenue $121.00K*; Research and development $75.33M*; Income tax (m); Net income -$81.32M*.
  • 2025-09-30: Revenue (m); Research and development $62.93M; Income tax (m); Net income -$67.04M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CLDX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Grant$15.00KService$7.00KRevenue$22.00KOperating income-$80.62MResearch & development$67.54MNet income-$73.50M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentIncome taxNet income
2026-06-30$22.00K$67.54M(m)-$73.50M
2026-03-31$15.00K$73.00M(m)-$78.69M
2025-12-31$121.00K*$75.33M*(m)-$81.32M*
2025-09-30(m)$62.93M(m)-$67.04M
2025-06-30$730.00K$54.20M(m)-$56.60M
2025-03-31$695.00K$52.61M(m)-$53.80M
2024-09-30$3.19M$45.26M(m)-$42.12M
2024-06-30$2.50M$39.69M(m)-$35.84M
2024-03-31$156.00K$31.66M(m)-$32.81M
2023-09-30$1.52M$34.53M(m)(m)
2023-06-30$268.00K$26.25M(m)(m)
2023-03-31$967.00K$26.80M(m)(m)
2022-09-30$407.00K$21.57M(m)(m)
2022-06-30$163.00K$20.73M(m)(m)
2022-03-31$174.00K$17.06M(m)(m)
2021-09-30$153.00K$13.56M-$227.00K(m)
2021-06-30$3.48M$12.36M(m)(m)
2021-03-31$685.00K$12.72M(m)(m)
2020-12-31$3.79M(m)$900.00K(m)
2020-09-30$668.00K$10.71M(m)(m)
2020-06-30$236.00K$9.71M-$200.00K(m)
2020-03-31$2.73M$11.70M(m)(m)
2019-12-31$887.00K(m)(m)(m)
2019-09-30$546.00K$11.10M(m)(m)
2019-06-30$715.00K$10.08M(m)(m)
2019-03-31$1.43M$11.15M(m)(m)
2018-12-31$1.76M(m)(m)(m)
2018-09-30$941.00K$11.92M(m)(m)
2018-06-30$2.76M$21.45M(m)(m)
2018-03-31$4.07M$21.88M-$765.00K(m)
2017-12-31$3.46M(m)(m)(m)
2017-09-30$3.92M$21.91M-$5.20M(m)
2017-06-30$3.83M$25.00M(m)(m)
2017-03-31$1.53M$25.79M(m)(m)
2016-12-31$1.87M(m)(m)(m)
2016-09-30$2.22M$25.01M(m)(m)
2016-06-30$1.39M$25.71M(m)(m)
2016-03-31$1.30M$27.45M(m)(m)
2015-12-31$1.79M(m)(m)(m)
2015-09-30$1.03M$24.66M(m)(m)
2015-06-30$2.18M$26.49M(m)(m)
2015-03-31$486.00K$25.13M(m)(m)
2014-12-31$1.48M(m)(m)(m)
2014-09-30$1.10M$26.18M(m)(m)
2014-06-30$592.00K$24.10M(m)(m)
2014-03-31$416.00K$27.07M(m)(m)
2013-12-31$620.00K(m)(m)(m)
2013-09-30$980.00K$20.42M(m)(m)
2013-06-30$97.00K$15.09M(m)(m)
2013-03-31$2.41M$14.09M(m)(m)
2012-12-31$3.65M(m)(m)(m)
2012-09-30$3.11M$11.77M(m)(m)
2012-06-30$2.01M$11.11M(m)(m)
2012-03-31$2.43M$10.77M(m)(m)
2011-12-31$2.43M(m)(m)(m)
2011-09-30$2.36M$8.59M(m)(m)
2011-06-30$1.95M$7.17M(m)(m)
2011-03-31$2.52M$6.85M(m)(m)
2010-09-30$2.41M$7.21M(m)(m)
2010-06-30$2.95M$7.26M(m)(m)

Revenue and expense 6 month

Period endRevenueResearch and developmentIncome taxNet income
2026-06-30$37.00K$140.54M(m)-$152.19M
2025-06-30$1.42M$106.81M(m)-$110.40M
2024-06-30$2.65M$71.35M(m)-$68.65M
2023-06-30$1.23M$53.05M(m)(m)
2022-06-30$337.00K$37.79M(m)(m)
2021-06-30$4.17M$25.08M(m)(m)
2020-06-30$2.96M$21.40M-$228.00K(m)
2019-06-30$2.14M$21.23M(m)(m)
2018-06-30$6.83M$43.32M-$765.00K(m)
2017-06-30$5.36M$50.79M(m)(m)
2016-06-30$2.69M$53.16M(m)(m)
2015-06-30$2.66M$51.62M(m)(m)
2014-06-30$1.01M$51.17M(m)(m)
2013-06-30$2.51M$29.18M(m)(m)
2012-06-30$4.44M$21.88M(m)(m)
2011-06-30$4.47M$14.02M(m)(m)
2010-06-30$6.66M$13.69M(m)(m)

Revenue and expense 9 month

Period endRevenueResearch and developmentIncome taxNet income
2025-09-30$1.42M$169.74M(m)-$177.44M
2024-09-30$5.84M$116.61M(m)-$110.77M
2023-09-30$2.75M$87.58M(m)(m)
2022-09-30$744.00K$59.36M(m)(m)
2021-09-30$4.32M$38.63M-$227.00K(m)
2020-09-30$3.63M$32.11M-$228.00K(m)
2019-09-30$2.69M$32.33M(m)(m)
2018-09-30$7.77M$55.24M-$765.00K(m)
2017-09-30$9.29M$72.71M-$5.20M(m)
2016-09-30$4.91M$78.17M(m)(m)
2015-09-30$3.69M$76.27M(m)(m)
2014-09-30$2.11M$77.36M(m)(m)
2013-09-30$3.49M$49.60M(m)(m)
2012-09-30$7.55M$33.65M(m)(m)
2011-09-30$6.83M$22.61M(m)(m)
2010-09-30$9.07M$20.91M(m)(m)

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-12-31$1.54M$200.00K$245.07M$0.00-$258.76M
2024-12-31$7.02M$200.00K$163.55M$0.00-$157.86M
2023-12-31$6.88M$300.00K$118.01M$0.00-$141.43M
2022-12-31$2.36M$100.00K$82.26M(m)-$112.33M
2021-12-31$4.65M$100.00K$53.31M-$227.00K-$70.51M
2020-12-31$7.42M$200.00K$42.53M-$1.17M(m)
2019-12-31$3.57M$100.00K$42.67M(m)(m)
2018-12-31$9.54M$700.00K$66.45M-$765.00K(m)
2017-12-31$12.74M$700.00K$96.17M-$24.28M(m)
2016-12-31$6.79M$1.60M$102.73M(m)(m)
2015-12-31$5.48M(m)$100.17M(m)(m)
2014-12-31$3.59M(m)$104.38M(m)(m)
2013-12-31$4.11M(m)$67.40M$0.00(m)
2012-12-31$11.20M(m)$47.40M$0.00(m)
2011-12-31$9.27M(m)$32.44M(m)(m)
2010-12-31$46.79M(m)$27.65M(m)(m)
2009-12-31$15.18M(m)$26.17M-$529.00K(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93